International Stem Cell Corp to Participate in Upcoming Investor Conference
September 27 2012 - 9:00AM
Marketwired
International Stem Cell Corporation (OTCQB: ISCO)
(www.internationalstemcell.com) ("ISCO" or "the Company"), a
California-based biotechnology company focused on therapeutic and
research products, today announced that Executive Vice President,
Dr. Simon Craw will attend and present at the SeeThru Equity Fall
Smallcap and Microcap Conference on October 2, 2012 at the Cornell
Club in midtown Manhattan, NY.
SeeThru Equity Fall Smallcap and
Microcap Conference Date: Tuesday, October 2,
2012 Time: 8:30 am EDT Location: The Cornell Club in midtown
Manhattan, NY
Please contact the conference organizers if you have an interest
in attending the conference or if you would like to arrange a
meeting with International Stem Cell's management team. You may
also contact Mark McPartland with MZ Group via email
markmcp@mzgroup.us or phone 1-212-301-7130 to arrange a meeting
with management.
You may register for the conference by clicking SeeThruEquity
Fall Conference Attendee Registration or visting the SeeThru Equity
website www.seethruequity.com
Additional information of the investor presentation will be
available on the investor relations section of the Company's
website www.internationalstemcell.com. A video replay webcast will
be available for viewing approximately 24hours after the company
presentation.
About International Stem Cell
Corporation
International Stem Cell Corporation is focused on the
therapeutic applications of human parthenogenetic stem cells
(hpSCs) and the development and commercialization of cell-based
research and cosmetic products. ISCO's core technology,
parthenogenesis, results in the creation of pluripotent human stem
cells from unfertilized oocytes (eggs) hence avoiding ethical
issues associated with the use or destruction of viable human
embryos. ISCO scientists have created the first parthenogenetic,
homozygous stem cell line that can be a source of therapeutic cells
for hundreds of millions of individuals of differing genders, ages
and racial backgrounds with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true
stem cell bank, UniStemCell™. ISCO also produces and markets
specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology
(www.lifelinecelltech.com), and stem cell-based skin care products
through its subsidiary Lifeline Skin Care
(www.lifelineskincare.com). More information is available at
www.internationalstemcell.com.
To receive ongoing corporate communications via email, visit:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company
updates and industry related news, visit:
www.facebook.com/InternationalStemCellCorporation and
www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments, scientific
program and clinical development goals and plans, potential sales
growth, new products and distribution channels and other
opportunities for the company and its subsidiaries, along with
other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as "will," "believes," "plans," "anticipates," "expects" or
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products and the
management of collaborations, regulatory approvals, need and
ability to obtain future capital, application of capital resources
among competing uses, and maintenance of intellectual property
rights. Actual results may differ materially from the results
anticipated in these forward-looking statements and as such should
be evaluated together with the many uncertainties that affect the
company's business, particularly those mentioned in the cautionary
statements found in the company's Securities and Exchange
Commission filings. The company disclaims any intent or obligation
to update forward-looking statements.
Contacts: International Stem Cell Corporation Dr. Simon
Craw Executive Vice President Phone: 760-940-6383 Email: Email
Contact Investor Relations: MZ Group Mark McPartland Senior Vice
President Phone: 212-301-7130 Email: Email Contact Web:
www.mzgroup.com
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Jul 2023 to Jul 2024